CAR T-Cell Therapy as a Second-Line Treatment for LBCL

News
Video

Miguel-Angel Perales, MD, shares insight into the factors he considers when deciding if a patient should receive CAR T-cell therapy in the second line.

Recent Videos
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Steven W. Pipe, MD, a professor of pediatric hematology/oncology at CS Mott Children’s Hospital
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
Michael Severino on In Vivo Gene Editing With RNA Gene Writers
Chris Wright, MD, PhD, on Annelloviruses, a Potential Alternative to AAV for Gene Therapy
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Related Content
CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – December 20, 2024

CGTLive Staff
December 20th 2024
Article

Review top news and interview highlights from the week ending December 20, 2024.

ImmunoLogic

CGTLive® Presents: ImmunoLogic, A Video Podcast With Joseph Fraietta, PhD

Joseph A. Fraietta, PhD;Noah Stansfield;Matt Hoffman
December 18th 2024
Podcast

Hosted by Joseph Fraietta, PhD, ImmunoLogic will be tailored for an audience fluent in the language of medicine and biotechnology, offering data-driven insights while maintaining accessibility.

FDA Approves Mesoblast’s Remestemcel-L for Steroid-Refractory GvHD

FDA Approves Mesoblast’s Remestemcel-L for Steroid-Refractory GvHD

Noah Stansfield
December 18th 2024
Article

The product will be marketed under the name Ryoncil, and is indicated for patients aged 2 months and older.

Around the Helix: Cell and Gene Therapy Company Updates – December 18, 2024

Around the Helix: Cell and Gene Therapy Company Updates – December 18, 2024

Noah Stansfield
December 18th 2024
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Molly Borchardt, PharmD

Pros and Cons of Various Reimbursement Models for Cell and Gene Therapies

Molly Borchardt, PharmD;Phil Cyr, MPH;Erin Lopata, PharmD, MPH;Jason Foster, MBA
December 16th 2024
Article

Cutting-edge cell and gene therapies have sparked ideas for new payment models that could reshape affordability and access to life-changing care.

Bristol Myers Squibb and 2seventy bio's CAR-T Ide-Cel Effects Responses in CNS-Involved R/R Multiple Myeloma

Bristol Myers Squibb and 2seventy bio's CAR-T Ide-Cel Effects Responses in CNS-Involved R/R Multiple Myeloma

Jonah Feldman
December 15th 2024
Article

Real-world data showed ide-cel was active in patients with central nervous system manifestations of multiple myeloma.

© 2024 MJH Life Sciences

All rights reserved.